This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Celgene (CELG) Down 6% Since Earnings Report: Can It Rebound?
by Zacks Equity Research
Celgene (CELG) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Biotech Stock Roundup: Puma Soars on Advisory Panel Vote, Priority Review for Kite Drug
by Arpita Dutt
Key highlights in the biotech sector include a favorable advisory panel vote for Puma (PBYI) and positive data and positive data from companies like Inovio and BioCryst.
The Zacks Analyst Blog Highlights: Regeneron, Amgen and Celgene
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Regeneron, Amgen and Celgene
Biotech Stock Roundup: FDA Nod for Regeneron RA Drug, Amgen Hit by Study Data
by Arpita Dutt
Key highlights in the biotech sector include FDA approval for Regeneron's (REGN) Kevzara and data from Amgen and Celgene.
Celgene (CELG) Multiple Sclerosis Drug Meets Primary Endpoint
by Zacks Equity Research
Celgene Corporation (CELG) announced positive results from the phase III trial, RADIANCE that evaluated the efficacy and safety of experimental candidate ozanimod.
Celgene's (CELG) Revlimid Looks Solid on Label Expansion
by Zacks Equity Research
Celgene's key growth driver, Revlimid, continues to outperform on the back of market share gains and increased duration.
Western Digital, Mattel, Celgene and Acceleron Pharma highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Western Digital, Mattel, Celgene and Acceleron Pharma highlighted as Zacks Bull and Bear of the Day
Why Shares of Biopharma Giant Celgene (CELG) Tumbled Today
by Madeleine Johnson
On Monday, shares of biopharmaceutical company Celgene Corp. (CELG) tumbled, and closed the day down 3.31% to $118.36 per share after one of its partners, Acceleron Pharma (XLRN), reported disappointing first-quarter results. XLRN stock closed down 12.79% to $27.69 per share.
Juno Therapeutics (JUNO) Posts Wider-than-Expected Q1 Loss
by Zacks Equity Research
Juno Therapeutics Inc. (JUNO) reported first-quarter 2017 loss of 71 cents per share (including stock-based compensation expenses), wider than the Zacks Consensus Estimate of a loss of 66 cents.
Agios (AGIO) Q1 Loss Narrower than Expected, Indhifa in Focus
by Zacks Equity Research
Agios Pharmaceuticals, Inc. (AGIO) posted first-quarter 2017 loss of $1.56 per share, narrower than the Zacks Consensus Estimate of a loss of $1.79 but wider than the year-ago loss of 61 cents.
Celgene vs. Amgen: Which Stock is a Better Pick Post Q1 Earnings?
by Arpita Dutt
Here is a look at how Celgene (CELG) and Amgen (AMGN) fared in the first quarter and which one looks better-positioned for the remainder of the year.
Biotech Stock Roundup: Amgen, Gilead, Celgene Q1 Earnings, Sunesis Down on Vosaroxin Update
by Arpita Dutt
Earnings were in focus this week with companies like Amgen (AMGN), Celgene, Vertex, AbbVie, Alexion and Gilead all reporting results over the last few days.
What's in Store for Juno Therapeutics (JUNO) in Q1 Earnings?
by Zacks Equity Research
Juno Therapeutics Inc. (JUNO) is scheduled to report first-quarter 2017 results on May 4, after the market closes.
Agios Pharmaceuticals (AGIO) Q1 Earnings: What's in Store?
by Zacks Equity Research
Agios Pharmaceuticals, Inc. (AGIO) is scheduled to report first-quarter results on May 4 before market open.
Celgene (CELG) Tops on Q1 Earnings, Sales Miss, Raises View
by Zacks Equity Research
Celgene's (CELG) first-quarter results were mixed, with the company beating on earnings but missing on sales.
Celgene (CELG) Beats On Q1 Earnings, Misses On Sales
by Ekta Bagri
Celgene beat on first-quarter 2017 earnings.
Pharma Stocks Q1 Earnings Roster for Apr 27: CELG, ABBV, BMY
by Zacks Equity Research
Celgene, AbbVie and Bristol-Myers Squibb are expected to report earnings on Apr 27.
Key Factors to Look Out for in Celgene's (CELG) Q1 Results
by Arpita Dutt
Apart from the usual earnings and revenue numbers, investors will be focused on the performance of Celgene's (CELG) key products and its pipeline progress.
Celgene (CELG) to Post Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Celgene Corporation (CELG) is scheduled to report first-quarter 2017 results on Apr 27, before the opening bell.
OncoMed Cancer Candidate Fails Trial, Bayer Opts Out of Deal
by Zacks Equity Research
It was a bad day for OncoMed Pharmaceuticals, Inc. (OMED) as it suffered two setbacks.
The Zacks Analyst Blog Highlights: Amazon, Celgene, Facebook and Walgreens Boots
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Amazon, Celgene, Facebook and Walgreens Boots
Top Research Reports for Today: AMZN, CELG, FB, WBA
by Mark Vickery
Today's Research Daily features new research reports on 17 major stocks, including Amazon (AMZN), Celgene (CELG), Facebook (FB) and Walgreens Boots (WBA).
Celgene (CELG) Gets Paragraph IV Notice Letter for Pomalyst
by Zacks Equity Research
Celgene Corporation (CELG) recently received a Paragraph IV Notice Letter advising that Teva Pharmaceutical Industries Limited (TEVA) submitted an ANDA to the FDA seeking an approval to manufacture and market a generic version of Pomalyst.
Biotech Stock Roundup: Acorda Down on Court Ruling, Patent Challenge for CELG Drug
by Arpita Dutt
Court rulings and patent challenges made headlines in the biotech sector with companies like Acorda (ACOR) and Celgene (CELG) providing updates.
Will These Three Drugs Continue Driving Celgene's Top-Line Growth?
by Arpita Dutt
With Revlimid going strong, Pomalyst and Otezla picking pace and potential blockbuster candidates in the pipeline, Celgene (CELG) looks well-positioned to maintain its growth trajectory.